Darwin AG: Subsidiary 305 Care starts with successful market launch

Munich 19.09.2024 (pta018/19.09.2024/10:00) - Darwin AG (ISIN DE000A3C35W0) announces that 305 Care GmbH ("305 Care"), a majority subsidiary of Darwin AG, has successfully entered the cosmetics market. 305 Care offers high-quality cosmetics through direct online sales. The products are dermatologically tested, vegan and were developed without animal testing.

The unique selling point of the product range is a care cream that is customized according to the specific skin characteristics of the customer and linked to the latest scientific findings. The technology required for this is provided by another Darwin subsidiary, Novogenia GmbH.

Since the first pre-launch of the products in April 2024, the average monthly growth in incoming orders has been +67% / month. 305care is now focused on continuing this successful growth trend in the 4th quarter, which is important for the cosmetics market, and later rolling it out internationally.

Further information about 305 Care can be found at https://305care.com/.

About Darwin AG

The "Darwin Group" (i.e. Darwin AG including its subsidiaries), headquartered in Munich (Germany), is a European biotechnology company, particularly in the field of human genetics. The genetic analyzes carried out in our own laboratory are used in diagnostics, therapy and prevention of diseases as well as in the production of individually designed nutritional supplements and cosmetics. Darwin also acts as a partner for doctors, therapists, pharmacists, nutritionists or fitness trainers and, by analyzing the respective genetic predisposition of the patient or customer, helps to ensure the best possible treatment or care for their needs. Darwin also invests in innovative companies in the biotech, healthcare and life sciences sectors.

(Ende)